Literature DB >> 26417586

Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

Wenhua Liang1, Qihua He1, Ying Chen1, Xusen Zou1, Lindsey Hamblin1, Jianxing He1.   

Abstract

Year:  2015        PMID： 26417586      PMCID： PMC4560697          DOI： 10.3978/j.issn.2305-5839.2015.08.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  5 in total

1.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

Review 2.  Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.

Authors:  Nathan A Pennell
Journal:  Clin Lung Cancer       Date:  2011-05-20       Impact factor: 4.785

3.  Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?

Authors:  Chun-Ming Tsai; Jen-Ting Chen; David J Stewart; Chao-Hua Chiu; Chun-Liang Lai; Shih-Yin Hsiao; Yuh-Min Chen; Kuo-Ting Chang
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

4.  Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.

Authors:  Naruo Yoshimura; Shinzoh Kudoh; Shigeki Mitsuoka; Naoki Yoshimoto; Takako Oka; Toshiyuki Nakai; Tomohiro Suzumira; Kuniomi Matusura; Yoshihiro Tochino; Kazuhisa Asai; Tatsuo Kimura; Tomoya Kawaguchi; Kazuto Hirata
Journal:  Lung Cancer       Date:  2015-06-15       Impact factor: 5.705

5.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316
  5 in total
  1 in total

1.  Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis.

Authors:  Jianxiang Song; Woda Shi; Yajun Zhang; Mingzhong Sun; Xiaodong Liang; Shiying Zheng
Journal:  Onco Targets Ther       Date:  2016-10-12       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.